Abstract
A 73-year-old woman was admitted to hospital with fever whilst under treatment with infliximab for rheumatoid arthritis. Despite repeated and specific testing, tuberculosis was only diagnosed post mortem. During infliximab therapy, latent tuberculosis can reactivate in subacute form with a possible fatal outcome. For infliximab therapy to be administered safely, the risk that the patient concerned is latently infected with tuberculosis has to be estimated beforehand; if necessary a prophylactic anti-tuberculosis treatment may be given.
| Translated title of the contribution | Fatal extrapulmonary tuberculosis during treatment with the immunosuppresive infliximab |
|---|---|
| Original language | Dutch |
| Pages (from-to) | 1196-1199 |
| Number of pages | 4 |
| Journal | Nederlands tijdschrift voor geneeskunde |
| Volume | 146 |
| Issue number | 25 |
| Publication status | Published - 22 Jun 2002 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- 2020 OA procedure
Fingerprint
Dive into the research topics of 'Fatal extrapulmonary tuberculosis during treatment with the immunosuppresive infliximab'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver